首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1643913

全球預防保健市場 - 2025-2032

Global Preventive Healthcare Market - 2025-2032

出版日期: 2025年01月27日 | 出版商:

DataM Intelligence | 英文 235 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球預防保健市場達到3,881.7億美元，預計2032年將達到11,616.5億美元，2024-2032年預測期間複合年成長率為14.1%。

預防保健是指定期進行健康檢查，並採取必要措施預防任何疾病的發生。在成年人中，預防保健是指對糖尿病、心血管疾病、癌症等疾病進行早期篩檢；在兒童中，疫苗接種、新生兒篩檢、遺傳性疾病基因檢測等是主要的預防保健措施。

市場動態：

驅動程式和限制

政府在預防性醫療保健方面的措施和投資不斷增加

全球各國政府不斷採取的促進預防性醫療保健實踐的措施預計將在未來顯著提振市場。隨著慢性病盛行率的上升，治療醫學的整體經濟負擔更高，因此各國政府正將重點轉向預防醫學。對疫苗接種、公共衛生監測、疾病篩檢計劃、早期診斷和宣傳活動等各種預防性醫療保健領域的投資正在不斷成長。

例如，2024年，法國AIS Agence de l'innovation en sante宣布投資170萬歐元（約1.8億美元），用於支持新型設備的開發以及與預防保健相關的其他研究活動。 AIS重點關注兒童健康、心理健康、不孕症、慢性病、傳染病、罕見疾病、成癮等八個領域，為大型項目、環境因素研究計劃等三個發展領域分配了預算以及開發預防技術的工業項目。

此外，Gavi也表示，在2026年至2030年期間，Gavi和疫苗合作夥伴計劃以巨額投資加強全球疫苗接種計畫。在此期間，疫苗聯盟計劃透過國內共同融資和自籌資金的疫苗計畫提供40億美元的財政捐助，拯救8至900萬人的生命，並為5億兒童提供免疫。

這些投資可以顯著改善公共衛生結果，減輕疾病負擔，減少昂貴的治療和住院的需要。

預防性醫療保健實踐的高成本可能會限制市場成長。

個人可能會發現預防性醫療措施昂貴，特別是如果他們必須自掏腰包的話。這可能會阻礙人們積極參與預防計劃或定期進行篩檢和檢查。實施全面的預防性醫療保健計劃通常需要在基礎設施、技術和人員培訓方面進行大量財務投資。

Preventive healthcare refers to the routine practice of healthcare checkups, and taking necessary measures to prevent the occurrence of any kind of disease. Among the adult population, preventive healthcare refers to early screening for conditions such as diabetes, cardiovascular diseases, cancers, etc, and among children, vaccination, newborn screening, genetic testing for inherited diseases, etc are the major preventive healthcare steps.

Market Dynamics: Drivers & Restraints

Rising government initiatives and investments in preventive healthcare

The rising initiatives by governments across the globe to promote the practice of preventive healthcare are expected to significantly boost the market in the future. With the rising prevalence of chronic conditions, the overall economic burden is higher for curative medicine, hence the governments are shifting their focus to preventive medicine. The investments are growing in various preventive healthcare sectors such as vaccinations, public health monitoring, disease screening programs, early-stage diagnostics, and awareness campaigns.

For instance, in 2024, Agence de l'innovation en sante, AIS of France announced an investment of €170 (~ US$180) million to support the development of novel devices and other research activities related to preventive healthcare. With a focus on eight fields such as children's health, mental health, infertility, chronic diseases, infectious disease, rare diseases, and addiction, AIS has allocated the budget for three development areas such as large-scale projects, a research program on environmental factors and industrial projects that develop preventive technologies.

Moreover, Gavi has stated that between the period of 2026-2030, Gavi and the vaccine partners plan to strengthen the global vaccination programs with huge investments. During the period, the vaccine alliance plans to save 8 to 9 million lives and immunize 500 million children through a financial contribution of US$ 4 billion through domestic co-financing and self-funded vaccine programs.

These investments can significantly improve public health outcomes, reduce the disease burden, reducing the need for expensive treatments and hospitalizations.

The high cost of preventive healthcare practices may restrain the market growth.

Individuals may find preventive healthcare measures expensive, especially if they have to bear the costs out-of-pocket. This can discourage people from actively participating in preventive programs or getting regular screenings and check-ups. Implementation of comprehensive preventive healthcare programs often requires substantial financial investments in infrastructure, technology, and personnel training.

Segment Analysis

The global preventive healthcare market is segmented based on type, application, and region.

Early-stage diagnostics in the application segment is expected to grow with the highest CAGR in the forecast period.

Early-stage diagnostics play a crucial role in preventive healthcare as they aid in the early detection of preventable diseases. Early-stage diagnosis refers to the identification of the disease risk and burden before the incidence of symptoms or in the initial stages. This can significantly reduce the disease and economic burden on the patient. There are several tools available for early-stage detection of various chronic and life-threatening diseases such as diabetes, heart stroke & other cardiovascular diseases, cancer, infectious diseases, etc. This early-stage detection allows for timely intervention before the disease incidence, and improve the overall patient outcome. The market for early-stage diagnostics is expected to significantly grow in the forecast period due to rising investments, launch of novel diagnostic tools and the increasing adoption rate by the population.

For instance, in December 2024, Strand Life Sciences, a subsidiary of Reliance Industries of India launched a new early cancer detection tool called CancerSpot. The test can detect multiple cancers from blood samples using Strand Life Science's proprietary sequencing technology. Moreover, in February 2024, All India Institute of Medical Sciences (AIIMS) Delhi launched a new Artificial Intelligence (AI) platform that enables the early detection of gynecological cancers.

Geographical Analysis

Asia-Pacific is expected to grow with the highest CAGR in the preventive healthcare market.

Asia-Pacific region is not only well known for its higher population but also for the advancing healthcare landscape. The growing elderly population and increasing prevalence of chronic non-communicable diseases are making the population highly aware of the importance of preventive measures. As per the World Health Organization statements 62% of all deaths in South East Asia are due to non-communicable diseases which account for 9 million persons. All these deaths could be avoided by the practice of preventive healthcare through early disease diagnosis, risk assessments, regular disease screening, health monitoring, etc. However, the practices of healthcare are rapidly changing in the region. The population of Asia-Pacific is rapidly becoming aware of the importance of preventive medicine. To further propel the practice, governments across the region are actively alocating budgets, launching screening programs, awareness campaigns for preventive healthcare.

For instance, for the financial year 2024-25, India's Ministry of Health and Family Welfare (MoHFW) has allocated a budget of Rs. 87,657 crores (~US$10.2 billion) for the for the Department of Health & Family Welfare (DoHFW). Moreover, Rs. 70,051 crore (~US$8.1 billion) grants for health through the local Governments were provided by the 15th Finance Commission. The health budget has seen a rise of 85% from the fiscal year 2017-18. In addition, till 10th December 2024, 1,75,418 Ayushman Arogya Mandirs (AAMs) have been established and operationalized whose function is to perform primary healthcare services including preventive medicine.

This huge makeshift in the healthcare practices in one of the fastest growing economies i.e., India reflects the region's investment in preventive healthcare.

Competitive Landscape

The major global players in the preventive healthcare market are Pfizer Inc., AstraZeneca, GSK plc., Sanofi, Merck & Co., Inc., Meridian Bioscience, Exact Sciences Corporation., GRAIL, Inc., Myriad Genetics, Inc., Apple Inc., SAMSUNG, Fitbit, Bio-Rad Laboratories, Inc., Revvity and Trivitron Healthcare among others.

Emerging Players

The emerging players in the preventive healthcare market include Chronomics Limited., CEREBRA.AI LTD, Aidoc, and iSchemaView, Inc. and ataraxis.ai, among others.

Key Developments

In October 2024, ataraxis.ai launched a novel AI-powered diagnostic test called Ataraxis Breast for precise and early detection of breast cancer. This tool can help physicians to prescribe personalized treatment to the patient and significantly improve the overall clinical outcome.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing innovations, and novel platform developments and forecasts upcoming technological advancements.
Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates user feedback and data into product/technology development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global preventive healthcare market report would provide approximately 69 tables, 48 figures, and 235 pages.

Target Audience 2023

Manufacturers: Pharmaceutical, Biotech Companies, Tech Leaders.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: R&D Professionals, Tech Innovators, AI Professionals.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising government initiatives and investments in preventive healthcare
  - 4.1.1.2. Rising awareness and practices of preventive healthcare
  - 4.1.1.3. Technological innovations for early disease screening
- 4.1.2. Restraints
  - 4.1.2.1. High cost of preventive healthcare
- 4.1.3. Opportunities
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Epidemiology
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Patent Analysis
5.6. Regulatory Analysis

6. By Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
6.2. Products*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Services

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Vaccination*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Early-Stage Diagnostics
  - 7.2.3.1. Cancer
  - 7.2.3.2. Diabetes
  - 7.2.3.3. Cardiovascular Diseases
  - 7.2.3.4. Hereditary Testing
  - 7.2.3.5. New Born Screening
  - 7.2.3.6. Others
7.3. Health Monitoring/Screening
7.4. Condition Management
7.5. Others

8. By Region

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.5.1. U.S.
  - 8.2.5.2. Canada
  - 8.2.5.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.5.1. Germany
  - 8.3.5.2. U.K.
  - 8.3.5.3. France
  - 8.3.5.4. Spain
  - 8.3.5.5. Italy
  - 8.3.5.6. Rest of Europe
8.4. South America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.5.1. Brazil
  - 8.4.5.2. Argentina
  - 8.4.5.3. Rest of South America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.5.1. China
  - 8.5.5.2. India
  - 8.5.5.3. Japan
  - 8.5.5.4. South Korea
  - 8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis

10. Company Profiles

Key Market Players

10.1. Pfizer Inc.*
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio
- 10.1.3. Financial Overview
- 10.1.4. Key Developments
- 10.1.5. SWOT Analysis
10.2. AstraZeneca
10.3. GSK plc.
10.4. Sanofi
10.5. Merck & Co., Inc.
10.6. Meridian Bioscience
10.7. Exact Sciences Corporation.
10.8. GRAIL, Inc.
10.9. Myriad Genetics, Inc.
10.10. Apple Inc.
10.11. SAMSUNG
10.12. Fitbit
10.13. Bio-Rad Laboratories, Inc.
10.14. Revvity
10.15. Trivitron Healthcare
Similar data will be provided for each market player.